一种基于aptamer的小RNA输送平台及其在癌症治疗中的应用
Toshihiko Tanno1,2, Peng Zhang2, Christopher Bailey2
1OncoC4, Inc., Rockville, MD 20850, USA.
Genes & diseases
|July 3, 2023
概括
研究人员开发了一种用于小RNA治疗的新型纳米粒子输送系统,增强稳定性并使得向向癌细胞的输送成为可能. 这一平台显示了改善基因沉默和瘤回归的前景,即使与免疫治疗结合使用.
科学领域:
- 生物技术是生物技术.
- 纳米医学是一种纳米医学.
- 在RNA治疗方面,RNA疗法.
背景情况:
- 小RNA疗法面临着诸如核酶降解,快速清除和不良传递等挑战,限制了临床使用.
- 现有的输送方法与特异性,细胞吸收和潜在的炎症反应作斗争.
研究的目的:
- 设计和评估一种新型的自组装纳米粒子平台,用于有针对性的小RNA输送.
- 克服当前RNA传递系统的局限性,以提高基因沉默和治疗疗效.
主要方法:
- 一个三氧核化物系统自组装成纳米粒子,具有胆固醇核心,RNA外和DNA吸收体.
- 纳米颗粒被设计为核酶耐药性,通过亚体进行向传递,以及内体逃生.
- 为乳腺癌研究创建了一个针对c-Kit的miR-26a传递粒子.
主要成果:
- 这些纳米粒子保护RNA免受降解,增加生物可用性并减少炎症.
- 实现了针对c-Kit+乳腺癌的向输送,增加T细胞招募并抑制瘤生长.
- 与抗CTLA-4单克隆抗体的联合治疗导致已建立瘤的回归.
结论:
- 新型纳米粒子平台有效地提供小RNA疗法,克服了关键的交付挑战.
- 有针对性的输送和增强的细胞内释放促进了强大的基因沉默和抗瘤活性.
- 这个平台在癌症治疗中具有组合疗法的潜力.
相关概念视频
Experimental RNAi
6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
siRNA - Small Interfering RNAs
16.9K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.9K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
RNA Interference
26.1K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.1K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Small interfering RNAs (siRNA)
3.6K
3.6K


